Clinical trialNo phase (not a drug trial)Unknown
Evaluation of the Impact of Pancreatectomy on Systemic Immunity
Pancreatic Surgery: Evaluation of the Impact of Pancreatectomy on Systemic Immunity
- Outcome
- Outcome unknown
- Phase
- No phase (not a drug trial)
- Status
- Unknown
- Study type
- Interventional
- Start
- 24 February 2021
- Listed end
- 27 July 2022
- Enrollment
- 40 participants
- Sites
- 1
- Primary outcomes
- Measurement of immune effectors (Tcells, NK) levels after pancreatectomy
- Sponsor type
- Academic / other
- Results posted
- No
- Last update
- 6 January 2022
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The study aims at establishing the profile of the immune reaction that occurs in the early surgical suites after pancreatectomy. Blood samples will be collected before surgery, (Day-1), at day0, and after surgery at Day 1, Day 3, Day 7 at 1 year after pancreatectomy. Mass cytometry, genomic and transcriptomic approaches will be used to evaluate the immune systemic modulation after surgery.